Description

Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer[1].—Cancer-programmed cell death–C72H96ClN17O14—-[1]Festuccia C, et al. Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9. –295350-45-7–1459.09—-OC(C=C1)=CC=C1C[C@H](N(C)C([C@H](CO)NC([C@H](NC([C@H](NC([C@H](NC(C)=O)CC2=CC3=C(C=CC=C3)C=C2)=O)CC4=CC=C(C=C4)Cl)=O)CC5=CN=CC=C5)=O)=O)C(N[C@H](CCCCNC(N)=O)C(N[C@@H](CCCC)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(N[C@H](C)C(N)=O)=O)=O)=O)=O)=O–Cancer–10 mM in DMSO–Apoptosis;GnRH Receptor—-Apoptosis;GPCR/G Protein–Peptides